Novavax to Participate in Upcoming September Conferences
09/09/2021 - 09:25 AM
GAITHERSBURG, Md. , Sept. 9, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
H.C. Wainwright 23rd Annual Global Investment Conference (Virtual)
Fireside Chat
Date:
Monday, September 13, 2021
Time:
Available on-demand starting at 7:00 a.m. Eastern Time (ET)
Moderator:
Vernon Bernardino
Novavax participants:
Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Panel
Date:
Wednesday, September 15, 2021
Time:
Available on-demand starting at 12:00 p.m. Eastern Time (ET)
Panel Title:
Best Practices – Planning for the Next Pandemic
Moderator:
Scott Gottlieb, M.D., Physician; Former Commissioner FDA
Panelist:
John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Morgan Stanley 19th Annual Global Healthcare Conference (Virtual)
Fireside Chat
Date:
Friday, September 10, 2021
Time:
2:00 – 2:30 p.m. Eastern Time (ET)
Moderator:
Jeffrey Hung
Novavax participants:
Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Recordings All replays of the recorded fireside sessions will be available through the events page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
About Novavax Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn .
Contacts: Investors Novavax, Inc. Erika Schultz | 240-268-2022ir@novavax.com
Solebury Trout Alexandra Roy | 617-221-9197aroy@soleburytrout.com
Media Alison Chartan | 240-720-7804Laura Keenan | 202-709-7521media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-upcoming-september-conferences-301372455.html
SOURCE Novavax, Inc.
NVAX Rankings
#5166 Ranked by Stock Gains
NVAX Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Gaithersburg
About NVAX
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.